← All indications
Central Nervous System Neoplasms
Benign and malignant neoplastic processes that arise from or secondarily involve the brain, spinal cord, or meninges.
Subtype terms (4)
More specific conditions that are subtypes of Central Nervous System Neoplasms in the MeSH hierarchy.
- Brain Neoplasms
591 drugs (291 approved, 300 experimental)
- Central Nervous System Cysts
- Meningeal Neoplasms
8 drugs (5 approved, 3 experimental)
- Spinal Cord Neoplasms
17 drugs (11 approved, 6 experimental)
Drugs by status
Phase 3 trials (15)
Phase 2 trials (29)
- abemaciclib
- mk-1775
- irinotecan
- lenalidomide
- cyproheptadine
- gemcitabine
- pembrolizumab
- larotrectinib
- megestrol
- motexafin gadolinium
- pazopanib
- ibrutinib
- pemetrexed
- ifosfamide
- elacestrant
- temozolomide
- bevacizumab
- topotecan
- abeotaxane
- ferumoxytol
- bortezomib
- cabozantinib
- nedaplatin
- oxaliplatin
- melphalan
- pomalidomide
- neratinib maleate
- tozuleristide
- oh2
Phase 1 trials (35)
- fhbg
- prexasertib
- apx005m
- autologous tumor infiltrating lymphocytes
- avelumab
- durvalumab
- fosbretabulin
- g207
- gallium citrate ga 67
- trametinib
- Filgrastim
- ribociclib
- lenvatinib
- memantine
- montanide isa 720
- perillyl alcohol
- avutometinib
- rrx-001
- sirolimus
- cyclosporine
- sonidegib
- tc99m-tilmanocept
- vinblastine
- vorinostat
- inactivated influenza vaccine
- neoantigen dna vaccine
- midazolam
- trebananib
- pentetic acid
- epothilone
- +5 more
Other trials (5)
Organizations
Organization Involved with Phase 4 Indications (3)
Organization Involved with Phase 3 Indications (59)
- Merck
- Pfizer
- Sugen
- Blaze Bioscience Inc.
- Colorado Health Foundation
- The Christie NHS Foundation Trust
- Medical Research Council
- National Cancer Institute (NCI)
- Maastricht University
- Canadian Cancer Trials Group
- Case Western Reserve University
- Cancer Research Campaign
- Centre Leon Berard
- Children's Cancer and Leukaemia Group
- University of London
- Eastern Cooperative Oncology Group
- Florida International University
- Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany
- Katholieke Universiteit Leuven
- McGill University
- NRG Oncology
- New York University
- North Central Cancer Treatment Group
- Radiation Therapy Oncology Group
- Southwest Oncology Group
- University of Heidelberg
- University of Lausanne
- University of Leicester
- University of Liverpool
- University of Nottingham
- +29 more
Organization Involved with Phase 2 Indications (102)
- Regeneron
- Eisai
- Celgene
- Cephalon
- Millennium Pharmaceuticals
- Bristol-Myers Squibb
- Roche
- Schering-Plough
- Agouron
- Novartis
- Bayer
- BeOne Medicines
- CTI BioPharma
- Cortice Biosciences, Inc.
- Direct Therapeutics
- Millennix
- Neurocrine Biosciences
- Oncovir, Inc.
- Avid Bioservices
- immatics Biotechnologies GmbH
- Agenus Inc.
- Turning Point Therapeutics
- National Institutes of Health (NIH)
- British Columbia Cancer Agency
- National Cancer Institute, France
- Rongjie Tao
- University of Pennsylvania
- University of Arizona
- University of Pittsburgh
- Atlantic Health System
- +72 more
Organization Involved with Phase 1 Indications (36)
- Daiichi Sankyo
- Pharmacyclics
- Wyeth
- Cavion LLC
- Ignyta, Inc.
- Oncoceutics, Inc.
- PTC Therapeutics
- SynerGene Therapeutics, Inc.
- Vion Pharmaceuticals
- EpicentRx, Inc.
- Sydney Children's Hospitals Network
- Xenova Biomedix
- Cancer Research UK
- University of Washington
- Indiana University
- Tata Memorial Hospital
- Tufts University
- University of Manchester
- University of Miami
- University of New Mexico
- West Virginia University
- University of Vermont
- University of Colorado, Denver
- Pacira Pharmaceuticals
- Cancer Immunotherapy Trials Network
- Astex Pharmaceuticals, Inc.
- University of Mannheim
- Institut de Cancerologie de l'Ouest Paul Papin
- Rush University
- University of Duisburg-Essen
- +6 more
Organization Involved with Other Experimental Indications (8)